1 June 2016 - NICE has published an appraisal consultation document for crizotinib (Xalkori) for use by patients with non-small-cell lung cancer.

NICE has commenced its appraisal of crizotinib for use by adults with untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

NICE does not recommend the first-line use of crizotinib at this time. This guidance is not intended to affect the position of patients whose treatment with crizotinib was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.

For more details, go to: https://www.nice.org.uk/guidance/GID-TA10012/documents/appraisal-consultation-document